New Issues in Heart Transplantation for Heart Failure

Heart Failure (J Fang, Section Editor)

DOI: 10.1007/s11936-012-0184-7

Cite this article as:
Kittleson, M.M. Curr Treat Options Cardio Med (2012) 14: 356. doi:10.1007/s11936-012-0184-7

Opinion statement

Heart transplantation is the preferred therapy for patients with end-stage heart failure with refractory symptoms despite optimal medical and device therapy. The major impediment to survival is rejection and infection in the short term and cardiac allograft vasculopathy and malignancy in the long term. Current therapies are focused on the prevention and treatment of rejection and limiting the long-term problems of cardiac allograft vasculopathy and malignancy. Advances in monitoring assays now allow better assessment of rejection and the level of immune response. This will allow clinicians, in the future, to tailor current therapies to the needs of individual heart transplant recipients to maximize benefit and minimize toxicity.


Heart failure Transplant Biopsy AlloMap Cylex Immunosuppression Corticosteroids Calcineurin inhibitors Antimetabolites Proliferation signal inhibitors Antithymocyte globulin Basiliximab Intravenous immunoglobulin Plasmapheresis Photopheresis Rituximab Bortezomib 

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Beverly HillsUSA

Personalised recommendations